Biocon Biologics Ltd (BBL) has recently announced that new dermatological data was presented at the European Academy of Dermatology and Venereology (EADV) 2024 Congress in Amsterdam. The results of two separate pivotal Phase 3 clinical studies indicated the interchangeability of adalimumab and adalimumab-fkjp, as well as the biosimilarity of bUstekinumab.
Uwe Gudat, M.D., Chief Medical Officer, Biocon Biologics stated, “The extensive range of new data being presented at EADV this year underscores Biocon Biologics’ commitment to a high-science portfolio of biosimilar medicines that meet the clinical needs of physicians and patients while providing important sustainability benefits to health systems. These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity without variation of clinical outputs in patients with chronic plaque psoriasis.”
